lift bioscience Investor gain investment in lift And Johnson & Johnson welcomes lift to Jlab
- Additional investment will support N-LIFT’s plans to enter clinics by Q1 2024
London, 19 December 2022 – LIFT BioSciences is pleased to announce that its lead investor, Starbloom Capital, has provided further investment in the company to accelerate LIFT’s R&D plans and advance N-LIFT. Infusion therapy) will move into clinical development by Q1 2024 within 15 months of showing strong preclinical results.
“Starbloom Capital participated in LIFT Biosciences’ first funding round in January 2022. We are very pleased to continue to support LIFT’s unique and truly innovative approach,” said James Fickel of Starbloom Capital. says Mr.
Additional funding is being deployed to support technology transfer to Good Manufacturing Practices for the use of N-LIFT in patients as LIFT moves into clinical trials. N-LIFT works by effectively transferring the innate immunity that some exceptional people have naturally in their bodies from stem cells to cancer patients. This treatment may give cancer patients about 20 times their natural ability to kill cancer. N-LIFT may overcome the hurdles faced by other cell therapies in treating solid tumors by:
- Allogeneic, easy to scale, cost effective, ready to use
- Destroys tumor cells in any form or indication with an innate antigen-independent mode of action
- Actively recruited to tumors with excellent invasion
- Stable and able to overcome the immunosuppressive tumor microenvironment
- It can mobilize the patient’s remaining immune system to join the attack and provide lasting immunity to that form of cancer.
LIFT also generated immunomodulatory alpha neutrophils (IMAN) from iPSCs and after showing very promising results transducing them with genetically engineered CAR add-ins, it launched its second generation product CAR-iN- We are doubling our investment in LIFT.
CEO Alex Blyth said: We are pleased to say that by Q1 2024 he will be able to move N-LIFT into clinical trials. He’s also amazed at how well the second-generation product is doing. It is my intention, through clinical trials, to make N-LIFT available to desperate patients as soon as possible as a broad-spectrum treatment to eradicate most solid tumors. If they do, we will deploy our 2nd generation product CAR-iN-LIFT to overcome these tumors as well. With our unique Alpha Neutrophil platform and product portfolio, we believe that every solid tumor can be destroyed and every challenge can be overcome, so no patient’s needs are left unanswered. A big thank you to our amazing team, investors and partners who made this possible. “
LIFT was also recognized as a resident of Johnson & Johnson Innovation – JLABS @ BE. JLABS is a global network of open innovation ecosystems that enable and empower innovators to accelerate the delivery of life-enhancing health and wellness solutions to patients around the world. As a leader in innovation, JLABS helps pharmaceutical, medical device, consumer and health tech entrepreneurs deliver healthcare solutions to patients and consumers.
|Alex Bryce||+44 (0)7718 759116||abilth@LIfTBioSciences.com|
|Consilium Strategic Communications Lindsey Neville, Namrata Taakemail@example.com|
Immunomodulatory alpha neutrophil (IMAN) imaging causes a lethal influx of calcium ions into tumor cells to destroy them.
This press release is subject to known and unknown risks, uncertainties and risks that could cause our actual results, performance or performance, or the performance of the industry, to differ materially from our stated future results, performance or performance. It contains forward-looking statements that include other factors that may or is implied by such forward-looking statements. LIFT BioSciences does not expect to continue to update its forward-looking statements as circumstances change.